Myriad Genetics
MYGN
MYGN
227 hedge funds and large institutions have $2.15B invested in Myriad Genetics in 2019 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 78 increasing their positions, 73 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
3% less capital invested
Capital invested by funds: $2.23B → $2.15B (-$73.6M)
37% less call options, than puts
Call options by funds: $8.74M | Put options by funds: $13.9M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
227
Holding in Top 10
1
Calls
$8.74M
Puts
$13.9M
Top Buyers
| 1 | +$71.2M | |
| 2 | +$31M | |
| 3 | +$20.1M | |
| 4 |
D.E. Shaw & Co
New York
|
+$9.93M |
| 5 |
Barclays
London,
United Kingdom
|
+$8.9M |
Top Sellers
| 1 | -$34.8M | |
| 2 | -$33.8M | |
| 3 | -$13.2M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.98M |
| 5 |
BAMCO Inc
New York
|
-$8.16M |